Form 4: Cytokinetics Director Wendell Wierenga Acquires Shares in Lieu of Cash Retainer
SEC Form 4 Filing
Director Wendell Wierenga acquired 127 shares of Cytokinetics Inc. common stock on January 2, 2025, in lieu of a cash retainer.
Summary
- On January 2, 2025, Wendell Wierenga, a director of Cytokinetics Inc., acquired 127 shares of common stock.
- The acquisition was made in lieu of a cash retainer, with the shares acquired at a price of $48.93 each.
- Following the transaction, Wierenga directly owns 24,686 shares of Cytokinetics Inc. common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects a routine transaction of a director acquiring shares in lieu of cash, which is neither particularly positive nor negative.
Positives
- Director's participation in the stock in lieu of cash retainer program demonstrates confidence in the company's future.
Industry Context
Directors often receive compensation in the form of stock to align their interests with those of shareholders. This is a common practice in publicly traded companies.
Stakeholder Impact
- The transaction could have a slightly positive impact on shareholders as it demonstrates the director's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of transaction: Director Wendell Wierenga acquired 127 shares of Cytokinetics Inc. common stock. |
| 01/06/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.